Quantcast

Latest genotype Stories

2015-04-25 12:22:45

- RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment VIENNA, April 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV)

2015-04-23 04:21:59

- Data from OPTIMIST-1 and OPTIMIST-2 Trials Showing SVR12 Rates of 97 Percent and 84 Percent to be Presented at The International Liver Congress(TM) 2015 of the European Association for the Study

2015-04-08 04:21:19

- 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline compounds NORTH

2015-02-12 00:21:30

- Submission based on Phase 3 GIFT-I study in patients with genotype 1b chronic hepatitis C virus infection NORTH CHICAGO, Ill., Feb.

2015-01-16 04:21:11

- In Phase 3 clinical trials, VIEKIRAX + EXVIERA cured 95-100 percent of genotype 1 chronic hepatitis C patients, with less than 2 percent of patients experiencing virologic failure[1],[2]

2015-01-12 23:06:00

A collaborative network designed to host, manage, analyze and share phenotypic and genotypic studies of plants and animals, Project Unity, in beta, is provided free of charge to the academic community.

2014-12-23 08:24:52

-- New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients -- In Phase 3 clinical trials, HOLKIRA

2014-12-19 20:21:35

- In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than 2 percent of patients experiencing virological failure NORTH CHICAGO, Ill., Dec.

2014-11-21 08:26:50

- Major regulatory milestone achieved toward approval in the European Union NORTH CHICAGO, Ill., Nov.


Word of the Day
coruscant
  • Emitting flashes of light; glittering.
The word 'coruscant' comes from a Latin word meaning 'to flash' or 'to sparkle'.
Related